Skip to Content
Søk Menu

IL17-hæmmere i rampelyset på EULAR 2023

EULAR 2023 viste en masse spændende tendenser inden for IL17-hæmmere, blandt andet nye Real World data og nye EULAR guidelines, hvor behandlingerne i højere grad bliver splittet op på de forskellige mode of actions herunder også IL-17 A og IL-17F hæmning. Få overblikket når Lars Erik Kristensen fra Parker Instituttet beskriver de seneste tendenser på IL17-området i denne MEDtalk.
Lars Erik Vølund Kristensen

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Sofia Ramiro

ASAS-EULAR Recommendations and Bimekizumab’s Novel Action in SpA

/ Sofia Ramiro
EULAR23PsASCR23 Play the Video 06:16

SCR 2023 – Four Days of Inspiring Data and Interdisciplinary Dialogue

/ Jan Andreasen
EULAR23PsASCR23SpA
Lars Erik Vølund Kristensen

PRO-spirit – Undersøgelse af behandlingsvedholdenhed hos voksne med psoriasisgigt

/ Lars Erik Kristensen
EULAR23PsoriasisSpA Play the Video 1:56
Marthe Kirkesæther Brun

Anti-Infliximab Antibodies Led to Poorer Clinical Outcomes

/ Marthe Kirkesæther Brun
EULAR23 Play the Video 06:25
Mikkel Østergaard

How To Diagnose Axial Involvement in Patients with Psoriasis or Psoriatic Arthritis?

/ Mikkel Østergaard
EULAR23PsoriasisPsoriasisartrit Play the Video 09:03
Rasmus Westermann

Does JAKi Increase the Risk of Cancer in Patients with RA?

/ Rasmus Westermann
EULAR23KreftRevmatoid artritt Play the Video 04:50

Patients with Inflammatory Diseases Should Get a Boost of COVID-19 Vaccine

/ Oliver Hendricks
Danish Centre for Expertise in RheumatologyEULAR23 Play the Video 05:07
Anna Døssing

Colchicine Twice Daily for Hand Osteoarthritis Doesn’t Relieve Pain

/ Anna Døssing
EULAR23 Play the Video 03:52

Improvement of Reproductive Healthcare for Patients with Rheumatic Diseases

/ Karen Schreiber
Danish Centre for Expertise in RheumatologyEULAR23 Play the Video 02:51
Back to top